Keyword: Richard Gonzalez
We're not gonna lie—Wednesdays at the J.P. Morgan Healthcare Conference feel a bit anticlimactic. But that doesn't mean the action has stopped.
Humira's best days may be past, but AbbVie could one day see $20 billion in combined sales for follow-ups Rinvoq and Skyrizi, CEO Rick Gonzalez said.
When the AbbVie/Allergan deal was unveiled in June, Allergan investors cheered, as AbbVie’s stock price sank. Analysts also have their doubts. While most viewed it as welcome news for Allergan, dubbing it a “graceful exit” for a “beaten-up name,” they raised multiple folds of concerns for AbbVie, the buyer.
AbbVie is plotting a $28 billion bond sale to help fund its massive Allergan buyout, Bloomberg reports, the fourth largest in history.
AbbVie's contribution to patient assistance groups and other nonprofits skyrocketed to about $350 million in 2018, from below $100 million in 2015.
AbbVie and Allergan’s $63 billion merger was a shock to the industry, but only talking to each other kept negotiations between CEOs under wraps.
AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.
Allergan investors have been pushing for action from management, and AbbVie has been hunting for new revenue streams. Now, they're set to combine.
AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch, an analyst writes.